



OPEN ACCESS

EDITED BY

Carolina Pellegrini,
University of Pisa, Italy

REVIEWED BY

Clelia Di Salvo,
University of Pisa, Italy
Cinzia Parolini,
University of Milan, Italy

*CORRESPONDENCE

Yazan Ranneh,
✉ yazan.ranneh@aaau.ac.ae

RECEIVED 24 May 2023

ACCEPTED 03 August 2023

PUBLISHED 17 August 2023

CITATION

Ranneh Y, Mahmoud AM, Fadel A,
Abu Bakar MF and Md Akim A (2023),
Comments on “Probiotic *Bifidobacterium*
strains and galactooligosaccharides
improve intestinal barrier function in
obese adults but show no synergism
when used together as synbiotics”.
Front. Pharmacol. 14:1228359.
doi: 10.3389/fphar.2023.1228359

COPYRIGHT

© 2023 Ranneh, Mahmoud, Fadel, Abu
Bakar and Md Akim. This is an open-
access article distributed under the terms
of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Comments on “Probiotic *Bifidobacterium* strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics”

Yazan Ranneh^{1*}, Ayman M. Mahmoud^{2,3}, Abdulmannan Fadel⁴,
Mohd Fadzelly Abu Bakar⁵ and Abdah Md Akim⁶

¹Department of Nutrition and Dietetics, College of Pharmacy, Al-Ain University, Al-Ain, United Arab Emirates, ²Zoology Department, Faculty of Science, Physiology Division, Beni-Suef University, Beni-Suef, Egypt, ³Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom, ⁴School of Sport and Exercise Sciences, Liver-Pool John Moores University, Liverpool, United Kingdom, ⁵Faculty of Applied Sciences and Technology, Universiti Tun Hussein Onn Malaysia (UTHM), Pagoh, Johor, Malaysia, ⁶Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

KEYWORDS

lipopolysaccharide, serum, *Bifidobacterium*, lipopolysaccharide binding protein, obesity

Introduction

The development of obesity is influenced by various factors; however, in recent decades, researchers have been particularly intrigued by the role of gut microbiota. Specific changes in bacterial taxa and a decrease in diversity within the gut microbiota are observed among obese individuals (Hou et al., 2017). These changes contribute to an elevation in intestinal permeability and translocation of lipopolysaccharide (LPS) into blood circulation, leading to metabolic endotoxemia (Mohammad and Thiernemann, 2021). LPS has been proven to increase tight junction permeability by inducing enterocyte membrane expression and localization of Toll-like Receptor-4 (Guo et al., 2013). Obesity has been linked to elevated intestinal permeability. In genetically obese mice, there is an upregulation of intestinal permeability along with an increase in circulating endotoxins and pro-inflammatory cytokines such as interleukin one beta (IL-1 β), interleukin-6 (IL-6), interferon-gamma (INF γ), and tumor necrosis factor (TNF- α), when compared to wild-type mice (Lee et al., 2018). Conversely, obesity induced by a high-fat diet, also known as diet-induced obesity (DIO), is associated with alterations in the gut microbial population that are associated with inflammation and heightened intestinal permeability, likely due to diminished expression of tight junction (TJ)-related genes, including ZO-1 and occludin. These collective observations indicate that obesity-related inflammation may be linked to disruptions in the integrity of TJ structures and alterations in the composition of the intestinal microbiota (Aleman et al., 2023).

Obese individuals have shown higher serum LPS concentrations along with TNF- α and IL-6. Among Mexican obese subjects, a positive correlation has been found between serum LPS and BMI, triglyceride, and waist circumference (Radilla-Vázquez et al., 2016). Thus, the assessment of serum endotoxin concentrations along with cytokines profile indicates the degree of systemic inflammation in obese individuals. Subsequently, several clinical trials have attempted to examine the effect of the administration of prebiotics and probiotics

(synbiotics) simultaneously on ameliorating metabolic endotoxemia (Fernandes et al., 2017). Serum LPS or LPS binding protein (LPB) concentrations were the main outcomes measured in those trials. Measuring LPS levels before and after interventions can provide insights into the effectiveness of synbiotics in reducing inflammation and improving gut health.

Discussion

Recently, Krumbeck et al. (2018) examined the effect of specific strains (*B.adolescentis* and *B.animals*) of *Bifidobacterium* along with galactooligosaccharides on intestinal permeability and endotoxemia among obese individuals. Metabolic markers, intestinal permeability, and endotoxin concentrations were measured in the study. This synbiotic treatment, composed of *Bifidobacterium* and galactooligosaccharides, enhanced the colonic permeability. During the study period, serum endotoxin was measured thrice. The authors concluded that no statistical significance was found in serum LPS and LBP among all the groups. However, the main drawback of the study is that the serum values of LPS and LBP were not presented either in the main manuscript or in the additional files section. It is unknown whether the baseline values of LPS and LBP are at high or low concentrations. Therefore, comparing the results of LPS and LBP with other clinical trials that used galactooligosaccharides or *Bifidobacterium* could not be applicable. Moreover, Krumbeck et al. (2018) did not consider measuring serum cytokines in the studied subjects. On the other hand, galactooligosaccharide supplementation led to a significant reduction in plasma LPS and C-reactive protein among obese individuals after 14 days of consumption (Morel et al., 2015). In addition, overweight and obese females who consumed *Bifidobacterium* for 8 weeks had lower levels of serum endotoxin compared with the control group (Gomes et al., 2017). Furthermore, compelling evidence suggests that prebiotics possess the capacity to bind with LPS within the intestinal lumen, effectively suppressing the translocation of LPS into the bloodstream (Snelson et al., 2021). Certain probiotic strains, particularly those belonging to the *Lactobacillus* and *Bifidobacterium* genera, assist in restoring the

integrity of the gut barrier and reduce intestinal permeability. By enhancing the production of tight junction proteins, probiotics can strengthen the barrier function of the intestinal lining, thereby limiting the translocation of LPS from the gut lumen into the blood circulation (Han et al., 2016).

Conclusion

In conclusion, the endotoxin findings by Krumbeck and her colleagues (2018) should be published in a specific corrigendum to illustrate the serum values of LPS and LBP. However, we suggest a deep discussion on the ineffectiveness of galactooligosaccharide over serum endotoxin levels and other inflammatory cytokines. Overall, this study is groundbreaking but further trials and testing are indispensable.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Aleman, R. S., Moncada, M., and Aryana, K. J. (2023). Leaky gut and the ingredients that help treat it: A review. *Molecules* 28, 619. doi:10.3390/molecules28020619
- Fernandes, R., do Rosario, V. A., Mocellin, M. C., Kuntz, M. G. F., and Trindade, E. B. S. M. (2017). Effects of inulin-type fructans, galacto-oligosaccharides and related synbiotics on inflammatory markers in adult patients with overweight or obesity: A systematic review. *Clin. Nutr.* 36, 1197–1206. doi:10.1016/j.clnu.2016.10.003
- Gomes, A. C., de Sousa, R. G. M., Botelho, P. B., Gomes, T. L. N., Prada, P. O., and Mota, J. F. (2017). The additional effects of a probiotic mix on abdominal adiposity and antioxidant status: A double-blind, randomized trial. *Obesity* 25, 30–38. doi:10.1002/oby.21671
- Guo, S., Al-Sadi, R., Said, H. M., and Ma, T. Y. (2013). Lipopolysaccharide causes an increase in intestinal tight junction permeability *in vitro* and *in vivo* by inducing enterocyte membrane expression and localization of TLR-4 and CD14. *Am. J. Pathol.* 182, 375–387. doi:10.1016/j.ajpath.2012.10.014
- Han, C., Ding, Z., Shi, H., Qian, W., Hou, X., and Lin, R. (2016). The role of probiotics in lipopolysaccharide-induced autophagy in intestinal epithelial cells. *Cell. Physiol. Biochem.* 38, 2464–2478. doi:10.1159/000445597
- Hou, Y. P., He, Q. Q., Ouyang, H. M., Peng, H. S., Wang, Q., Li, J., et al. (2017). Human gut microbiota associated with obesity in Chinese children and adolescents. *Biomed. Res. Int.* 2017, 7585989. doi:10.1155/2017/7585989
- Krumbeck, J. A., Rasmussen, H. E., Hutkins, R. W., Clarke, J., Shawron, K., Keshavarzian, A., et al. (2018). Probiotic *Bifidobacterium* strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. *Microbiome* 6, 121. doi:10.1186/s40168-018-0494-4
- Lee, J. Y., Wasinger, V. C., Yau, Y. Y., Chuang, E., Yajnik, V., and Leong, R. W. L. (2018). Molecular pathophysiology of epithelial barrier dysfunction in inflammatory bowel diseases. *Proteomes* 6, 17. doi:10.3390/PROTEOMES6020017
- Mohammad, S., and Thiernermann, C. (2021). Role of metabolic endotoxemia in systemic inflammation and potential interventions. *Front. Immunol.* 11, 594150. doi:10.3389/fimmu.2020.594150
- Morel, F. B., Dai, Q., Ni, J., Thomas, D., Parnet, P., and Fañca-Berthon, P. (2015). α -Galacto-oligosaccharides dose-dependently reduce appetite and decrease inflammation in overweight adults. *J. Nutr.* 145, 2052–2059. doi:10.3945/jn.114.204909
- Radilla-Vázquez, R. B., Parra-Rojas, I., Martínez-Hernández, N. E., Márquez-Sandoval, Y. F., Illades-Aguir, B., and Castro-Alarcón, N. (2016). Gut microbiota and metabolic endotoxemia in young obese mexican subjects. *Obes. Facts* 9, 1–11. doi:10.1159/000442479
- Snelson, M., de Pasquale, C., Ekinci, E. I., and Coughlan, M. T. (2021). Gut microbiome, prebiotics, intestinal permeability and diabetes complications. *Best. Pract. Res. Clin. Endocrinol. Metab.* 35, 101507. doi:10.1016/j.beem.2021.101507